Business, energy, technology, markets and global industry news from Business News Today

whole-genome sequencing

PharmaDeviceNews whole-genome sequencing
Representative image: A clinical genomics researcher reviews whole-genome sequencing data, reflecting Inocras’ ASCO 2026 findings on WGS-HRD testing and PARP inhibitor benefit in high-grade serous ovarian cancer.
Medical Devices & Diagnostics

Can Inocras’ whole-genome HRD data change how ovarian cancer patients are selected for PARP maintenance?

PARP selection still leaves gaps. Inocras’ WGS-HRD data suggest whole-genome testing may refine ovarian cancer maintenance decisions.

Read More
Representative image of a clinical diagnostics lab reviewing blood-based MRD test results, as Veracyte’s TrueMRD Medicare coverage decision pushes whole-genome bladder cancer recurrence monitoring closer to routine oncology care.
Medical Devices & Diagnostics

Veracyte’s TrueMRD Medicare win pushes whole-genome MRD testing into bladder cancer surveillance

MRD testing is moving from research to reimbursement. Veracyte now has Medicare coverage, but adoption in bladder cancer care is the harder test.

Read More
Representative image: Veracyte’s Medicare coverage win for the TrueMRD bladder cancer recurrence monitoring test highlights the growing role of blood-based molecular diagnostics in detecting muscle-invasive bladder cancer recurrence earlier and supporting more precise post-treatment surveillance.
Medical Devices & Diagnostics

Why Veracyte’s Medicare win for TrueMRD could reshape bladder cancer recurrence monitoring

MRD testing has payer momentum, but clinical adoption is tougher. Veracyte’s TrueMRD Medicare win puts bladder cancer monitoring in focus.

Read More